TRINOMAB

Zhuhai Trinomab Biopharmaceutical Co., Ltd. (hereafter referred to as "Trinomab"), is a biopharmaceutical company dedicated to developing and commercializing the innovative therapeutics on a global scale. Founded in 2015 and guided by the philosophy "Creating Clinical Value for Patients", the company is committed to advancing its proprietary HitmAb® technological platform. This platform facilitates the discovery and manufacturing of fully human monoclonal antibodies (mAbs), which serve as alternatives to blood-derived immunoglobulin products... Trinomab is making the transition from an early R&D biotech company to a biopharmaceutical company and eventually a global pharmaceutical

Primary location: Dover United Kingdom